| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,037,590 | -214,239 |
| Forgiveness of unrelated vendor payables | 2,142,297 | 2,142,297 |
| Depreciation | 1,285 | 743 |
| Change in fair value of deferred underwriting fee - common stock payable | -196,000 | -756,000 |
| Change in the fair value of warrant liabilities | 40,023 | 116,894 |
| Issuance of common stock in connection with the surrender of warrants | -1,740,000 | - |
| Due from related party, current | 3,427,000 | 3,427,000 |
| Prepaid and other current assets | -8,660 | -43,442 |
| Accounts payable and accrued expenses | -4,058,404 | -2,043,405 |
| Accrued interest, related parties | -196,852 | -177,800 |
| Accrued maintenance fee | - | 360,000 |
| Due to research and development partner | - | 1,782,297 |
| Due to related party | -94,000 | -101,500 |
| Net cash used in operating activities | -9,576,471 | -8,975,859 |
| Loans to iris acquisition corp | 775,000 | 775,000 |
| Purchases of property and equipment | 13,108 | - |
| Net cash used in investing activities | -788,108 | -775,000 |
| Gross proceeds from issuance of common stock for pipe investment | 10,556,500 | 10,556,500 |
| Payment of transaction costs | 2,563,738 | 2,563,738 |
| Proceeds from issuance of short-term debt, related party | 4,340,000 | 4,340,000 |
| Repayment of short-term debt, related party | 1,300,000 | 1,300,000 |
| Net cash provided by financing activities | 11,032,762 | 11,032,762 |
| Net change in cash | 668,183 | 1,281,903 |
| Cash and cash equivalents at beginning of period | 56,319 | 56,319 |
| Cash and cash equivalents at end of period | 724,502 | 1,338,222 |
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)